Partial clinical improvement in Upshaw-Schulman syndrome following prostacyclin infusion.

Abstract

We report on a Japanese girl with Upshaw-Schulman syndrome, a congenital disorder characterized by recurrent thrombocytopenia, microangiopathic hemolytic anemia, proteinuria and hematuria that can be transiently improved by the transfusion of plasma or various plasma components. Unusually Large von Willebrand Factor (ULvWF) multimers were found during both relapse and remission phases. Serial plasma levels of 6-keto-prostaglandin F1 alpha (PGF1 alpha), the stable metabolite of prostacyclin (PGI2), were low at relapse. When the patient was treated with continuous PGI2 infusion, the microangiopathic hemolytic process gradually subsided within 10 days. These results suggest that PGI2 may be partly involved in the pathogenesis of this congenital disorder.

• Authors: M Konno, A Yoshioka, T Takase, T Imai
• Journal: Acta paediatrica Japonica : Overseas edition (Acta Paediatr Jpn) Vol. 37 Issue 1 Pg. 97-100 (Feb 1995) ISSN: 0374-5600 [Print] Australia
• PMID: 7754778 (Publication Type: Case Reports, Journal Article)

Chemical References

• von Willebrand Factor
• Epoprostenol

Topics

• Anemia, Hemolytic, Congenital (blood, therapy)
• Epoprostenol (administration & dosage, blood)
• Female
• Humans
• Infant
• Recurrence
• Syndrome
• Thrombocytopenia (blood, congenital, therapy)
• von Willebrand Factor (metabolism)